Previous Article | Next Article ![]()
Journal of Virology, May 1999, p. 4502-4507, Vol. 73, No. 5
Division of Pulmonary Medicine, Children's
Hospital Research Foundation, Cincinnati, Ohio 45229-3039
Received 20 October 1998/Accepted 19 January 1999
Respiratory syncytial virus (RSV) infection of airway epithelial
cells results in persistent NF- Respiratory syncytial virus (RSV)
infection in the airway is a major cause of morbidity and mortality in
children (7). In vitro and in vivo studies have demonstrated
that the pathophysiology of RSV infection involves airway inflammation
(17). A key component to the inflammatory response is the
production of proinflammatory mediators, such as interleukin-1 (IL-1),
IL-6, IL-8, tumor necrosis factor alpha (TNF- In unstimulated cells, NF- Studies in our lab and others have demonstrated that A549 cells respond
to RSV infection similarly to primary airway cells in culture (2,
11). For all experiments, the A549 cells were between passages 80 and 95. The cells were maintained in Dulbecco's modified Eagle's
medium (DMEM) supplemented with lipopolysaccharide-free 8% fetal calf
serum and 2 mM L-glutamine. No antimicrobial agents were
used at any time, and the cells were free of mycoplasma infection. The
cells were infected with RSV by adding the virus at a multiplicity of
infection of 1.0 in DMEM for 2 h. The RSV-containing DMEM was then
removed, and the cells were washed several times with DMEM.
Previous studies have demonstrated that RSV infection of airway
epithelial cells results in persistent NF- Following RSV infection, NF-
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Incomplete Regulation of NF-
B by I
B
during
Respiratory Syncytial Virus Infection in A549 Cells
![]()
ABSTRACT
Top
Abstract
Text
References
B activation and NF-
B-mediated interleukin-8 production. Previous studies in airway epithelial cells
demonstrated that tumor necrosis factor alpha (TNF-
)-induced NF-
B
activation is transient due to regulation by I
B
. However, during
RSV infection, I
B
has only a partial inhibitory effect on NF-
B
activation. Studies presented here demonstrate that neither increased
I
B
production which occurs as a result of RSV-induced NF-
B
activation nor inhibition of proteasome-mediated I
B
degradation results in a reversal of RSV-induced NF-
B activation. Thus, while manipulation of I
B
results in reversal of TNF-
-induced NF-
B activation, manipulation of I
B
does not result in a reversal of
RSV-induced NF-
B activation.
![]()
TEXT
Top
Abstract
Text
References
), and
granulocye-macrophage colony-stimulating factor, by airway epithelial
cells (18). All of these proinflammatory mediators are
regulated at the level of gene transcription by the nuclear factor
NF-
B (3). Studies in our and other labs have demonstrated
that RSV replication in airway epithelial cells is associated with
NF-
B activation (5, 8, 12). Therefore, amelioration of
NF-
B activation offers a potential means of reversing RSV-induced inflammation.
B is sequestered in the cytoplasm by
inhibitors in the I
B family (3). Studies using A549 cells have demonstrated that with TNF-
stimulation, I
B
is targeted for degradation within 5 to 10 min (10). This is associated with NF-
B activation (10, 14). However, when the cells
are treated with the proteasome inhibitor MG-132, I
B
degradation and NF-
B activation are reversed. The studies presented here were
designed to determine whether augmentation of I
B
protein levels
was associated with a reversal of RSV-induced NF-
B activation.
B activation. Therefore, our focus in this study was on whether newly synthesized I
B
could
inhibit RSV-induced NF-
B activation and whether inhibition of
I
B
degradation would limit RSV-induced NF-
B activation.
B activation was observed for up to
72 h by electrophoretic mobility shift assays (EMSA)
(9) of nuclear extracts (Fig.
1B). The NF-
B probe consisted of a 32P-labeled double-stranded DNA corresponding to the
NF-
B binding site present in the IL-8 gene. The sequence of the
probe is CAGCTACGCAGCGTGGAATTTCCT, which corresponds to a
mutated NF-IL-6 site that does not bind NF-IL-6 (data not shown) and an
intact NF-
B site from the IL-8 gene (15, 16). As
illustrated in Fig. 1B (which is representative of five experiments),
control cells had minimal NF-
B activation. In contrast, in
RSV-infected cells, NF-
B activation was apparent 24 h after
infection and remained elevated at 48 and 72 h after infection.

View larger version (79K):
[in a new window]
FIG. 1.
(A) Western blot analysis of cytosolic proteins. Fifty
micrograms of cytosolic protein extract from control (C) or
RSV-infected (R) cells was subjected to Western blot analysis using a
polyclonal antibody to I
B
. Numbers at the top indicate hours
after RSV infection. Protein detection was performed with a
commercially available enhanced chemiluminescence detection kit. (B)
EMSA analysis of nuclear extract proteins, performed with a DNA probe
consisting of the IL-8 NF-
B binding region for control (C) and
RSV-infected (R) cells. Numbers at the top indicate hours after RSV
infection; 10 µg of total protein was used for each condition.
Western blot analysis was used to determine the effects of RSV
infection on I
B
protein levels. A549 cells were infected with
RSV, and cytoplasmic extracts were obtained 24, 48, and 72 h after
infection. As illustrated in Fig. 1A (which is representative of five
experiments), 24 h after infection, I
B
levels are lower in
RSV-infected cells than in control cells. However, I
B
is still
detectable in the RSV-infected cells. This is in contrast to TNF-
stimulation, which results in complete loss of I
B
, as previously
reported (10, 14). Furthermore, in RSV-infected cells,
I
B
levels approach those of control cells at 48 and 72 h.
Thus, RSV infection is associated with an initial decline in I
B
levels, though near-control levels are detected later in the infection.
However, NF-
B activation persists despite the near-control levels of
I
B
, suggesting that I
B
cannot inhibit NF-
B nuclear
translocation and DNA binding in the RSV-infected cells.
In other cell types, activation of NF-
B has been associated with
increased I
B
gene expression (13). Three NF-
B
binding sites are present in the 5' flanking region of the I
B
gene (13). By increasing I
B
gene expression and
protein production, NF-
B essentially down-regulates its own
activation. To determine whether RSV-induced NF-
B activation was
associated with I
B
gene expression, Northern blot analysis was
performed. As illustrated in Fig. 2A, at
24, 48, and 72 h after infection I
B
mRNA expression is
higher in RSV-infected cells than in controls. The increase in I
B
mRNA expression occurs during viral replication, as evidenced by
expression of the RSV F gene (8). Thus, this result
indicates that increased I
B
mRNA expression is associated with
viral replication during RSV infection.
|
The next experiment was designed to determine whether the increase in
I
B
mRNA levels observed with RSV infection was due to
prolongation of the I
B
mRNA half-life. Control and RSV-infected cells were treated with actinomycin D for 1, 2, or 4 h, and
Northern blot analysis performed on cellular RNA. As illustrated in
Fig. 2B, treatment with 10 µg of actinomycin D per ml results in
decreased I
B
mRNA expression in both control and RSV-infected
cells. Furthermore, as illustrated in Fig. 2C, the slope of the
degradation curve for the I
B
mRNA signal in RSV-infected cells
was identical to the slope of the curve in control cells. The curve for
the RSV-infected cells was shifted upward due to a higher initial
expression level of I
B
in RSV-infected cells. This result
indicates that the increase in I
B
mRNA expression in RSV-infected
cells is not due to stabilization of the message but likely is due to
increased gene transcription.
The next experiment was designed to determine whether RSV infection
resulted in the synthesis of I
B
protein. Control and RSV-infected
cells were placed in methionine- and cysteine-free medium for 4 h,
and then 35S-labeled methionine and cysteine were added.
Cells lysates were obtained and subjected to protein precipitation
using an antibody to I
B
. The resulting precipitate was subjected
to electrophoresis on a 10% Tris-glycine gel. As illustrated in Fig.
3, minimal I
B
is detected in
control cells (lane 1). However, in RSV-infected cells (lane 2), two
bands are detected at the appropriate size for I
B
and
phosphorylated I
B
. This result indicates that RSV infection is
associated with increased I
B
protein synthesis in A549 cells.
|
It was intriguing that I
B
protein levels were increasing after
24 h, but there was no apparent inhibition of NF-
B activation. This result indicates that NF-
B-regulated I
B
production did not result in effective inhibition of NF-
B activation as was previously reported for TNF-
stimulation (22). To
determine whether I
B
production had any effect on RSV-induced
NF-
B activation, the next set of experiments were performed to
determine the effects of limiting I
B
gene expression and the
effects of limiting I
B
protein production during RSV infection.
To determine whether limiting RSV-induced I
B
mRNA expression
altered NF-
B activation, control and RSV-infected cells were treated with actinomycin D for 4 h. As illustrated in Fig. 2B, this results in decreased I
B
mRNA expression. Treatment with actinomycin D also resulted in decreased I
B
protein detection (data not shown). EMSA analysis of nuclear extracts for NF-
B activation is illustrated in Fig. 4A.
Treatment of control cells with actinomycin D resulted in greater
NF-
B activation than in untreated control cells (Fig. 4A; compare
lanes 1 and 2). Furthermore, treatment of RSV infected cells with
actinomycin D for 4 h resulted in a greater NF-
B response than
in untreated RSV-infected cells (Fig. 4A; compare lanes 3 and 4). This
result is consistent with the notion that inhibition of I
B
mRNA
expression results in an exaggerated NF-
B response during RSV
infection.
|
The next experiment focused on determining whether inhibition of
I
B
protein synthesis would alter RSV-induced NF-
B activation. Control and infected cells were treated with 10 µg of cycloheximide per ml for 4 h. As illustrated in the Western blot in Fig. 4B, a
small difference in I
B
protein detection is observed between control (lane 1) and RSV-infected (lane 2) cells. Treatment of control
cells with cycloheximide had little effect on I
B
protein detection in control cells (lane 3) but had a marked effect on I
B
protein detection in RSV-infected cells (lane 4).
Analysis of nuclear extracts for NF-
B activation by EMSA analysis is
illustrated in Fig. 4C. Treatment of control cells with cycloheximide
resulted in no apparent difference in NF-
B activation (compare lanes
1 and 3). However, treatment of RSV-infected cells with cycloheximide
resulted in an increase in NF-
B activation (compare lanes 2 and 4).
Together, the data from Figs. 4B and C indicate that inhibition of
I
B
protein synthesis during RSV infection is associated with an
increase in NF-
B activation.
The combined results from the experiments using actinomycin and those
using cycloheximide indicate that inhibition of I
B
mRNA
expression and I
B
protein synthesis results in a exaggerated response to RSV infection with respect to NF-
B activation. The results of these experiments are consistent with (but not proof of) the
notion that RSV-induced I
B
mRNA expression and protein synthesis
are important in at least partially limiting NF-
B activation.
As illustrated in Fig. 1A, on days 1, 2, and 3, RSV-infected cells
contained less I
B
than control cells, which indicates that
I
B
degradation was occurring during RSV infection. The next set
of experiments was designed to determine whether inhibition of
RSV-induced I
B
degradation would result in altered NF-
B activation in response to RSV. For these studies, control cells or
cells infected with RSV were treated with various concentrations of the
proteasome inhibitor MG-132 for 2 h. Previous studies in our lab
demonstrated that treatment of A549 cells with MG-132 reversed
TNF-
-induced NF-
B activation by limiting I
B
degradation (10).
The results of the experiments using the proteasome inhibitor MG-132
are illustrated in Fig. 5. Western blot
analysis (Fig. 5A) demonstrates that treatment of control and
RSV-infected cells with increasing concentrations of MG-132 results in
increased I
B
protein detection. The I
B
bands detected in
the MG-132 treated cells migrated slightly more slowly than those not
treated with MG-132. Previous studies in our lab using MG-132 indicated that the bands represented phosphorylated I
B
(10).
Western blot analysis using an antibody to phosphorylated
I
B
confirmed that the slower-migrating bands were
phosphorylated I
B
(data not shown). Thus, treatment of
RSV-infected cells with the proteasome inhibitor MG-132 resulted in
reversal of I
B
protein loss but not I
B
phosphorylation.
|
To determine whether inhibition of proteasome-mediated I
B
degradation resulted in a reversal of RSV-induced NF-
B
activation, EMSA analysis of nuclear extracts was performed. As
illustrated in Fig. 5B, treatment with increasing concentrations of
MG-132 had a partial effect on reversing RSV-induced NF-
B
activation. Thus, despite the observation that treatment with MG-132
resulted in complete reversal of RSV-induced I
B
degradation, only
a partial reversal of RSV-induced NF-
B activation was observed.
An interesting finding from the EMSA analysis in Fig. 5B was that
treatment with MG-132 resulted in a slower-migrating NF-
B-DNA complex. The next experiment was designed to characterize this complex.
As illustrated in Fig. 6, comparison of
lane 1 (control cells) to lane 2 (RSV-infected cells) confirms that
NF-
B activation is present during infection. Treatment of infected
cells with 100 µM MG-132 results in a decrease in the NF-
B signal
which is slower migrating (lane 3). When EMSA analysis of the same
extracts from lane 3 is performed in the presence of a 100-fold excess of unlabeled NF-
B DNA probe, the signal is completely abolished (lane 4), indicating that the slower-migrating signal represents NF-
B-DNA binding.
|
Lanes 5 to 10 in Fig. 6 represent attempts to supershift the
NF-
B-DNA complex with polyclonal antibodies to individual potential components of NF-
B. The nuclear extracts used are from RSV-infected cells treated with 100 µM MG-132 for 2 h. The addition of
antibodies to p65 (lane 5) and p50 (lane 7) resulted in supershifting
of the NF-
B DNA complex. However, addition of antibodies specific for c-Rel (Lane 6) and p52 (Lane 8) did not result in any alterations in binding of NF-
B to the DNA probe, nor did they affect migration of the complex. Our results confirms an earlier finding by Bitko et al.
(5). Furthermore, this result indicates that the
slower-migrating complex observed in lane 3 is composed at least in
part of p65 and p50 and does not represent heterodimers involving c-Rel
or p52.
Since MG-132 inhibits the degradation of I
B
, we attempted to
determine whether I
B
could be complexed to NF
B while bound to
the DNA probe. Therefore, two different commercially available polyclonal antibodies to I
B
(C-15 [Fig. 6, lane 9] and C-21 [lane 10]; Santa Cruz Biotechnology) were added to the EMSA
reactions. Neither of these antibodies resulted in supershifting of the
NF-
B-DNA signal or competitive inhibition of binding of NF-
B to
DNA probe. To further investigate whether I
B
remained bound to
NF-
B during treatment with MG-132, whole-cell extracts were
subjected to protein precipitation using a polyclonal antibody to p65.
The precipitated protein was subjected to Western blot analysis using
an antibody to I
B
(C-21). As illustrated in Fig.
7, the I
B
protein is easily
detected in control cells (lane 1). However, in RSV-infected cells,
less I
B
coprecipitated with the p65 antibody (lane 2). Furthermore, no increase in I
B
coprecipitation with the p65 antibody was observed with RSV-infected cells treated with 100 µM
MG-132 (lane 3). Thus, treatment with MG-132 does not result in
increased p65-I
B
binding. Combined, the results of the EMSA analysis and coprecipitation studies do not support the notion that the
slower-migrating NF-
B-DNA signal observed in MG-132-treated cells
infected with RSV is due to persistent I
B
binding. Furthermore, the coprecipitation study indicates that despite the observation that
MG-132 results in decreased I
B
degradation, it does not increase
binding of I
B
to p65.
|
The EMSA analysis in Fig. 5B indicates that treatment of RSV-infected
cells with 100 µM MG-132 resulted in a small decrease in NF-
B
activation. To determine whether this was of biological significance,
the effects of RSV infection on IL-8 gene transcription and IL-8
protein production were determined. IL-8 gene transcription was
assessed in a luciferase reporter assay previously described (9). In this assay, NF-
B-mediated IL-8 gene transcription is responsible for luciferase activity measured in cell lysates. Luciferase activity was measured in cells transfected with the reporter
plasmid (controls) and cells transfected with the reporter plasmid and
infected with RSV. For the control cells (n = 12), each
of the individual values is divided by the mean in order to obtain a
standard deviation. For the RSV-infected cells, each of the individual
values (n = 12) is divided by the mean of the control
cell values. Therefore, the values are reported as an increase in
luciferase activity as a function of RSV infection. As illustrated in
Fig. 8A, RSV infection of A549 cells
results in a nearly sevenfold increase in luciferase activity (and
therefore IL-8 gene transcription). Treatment with 100 µM MG-132 for
4 h resulted in a small but statistically significant (P < 0.05 by analysis of variance [ANOVA], n = 12)
decrease in luciferase activity (Fig. 8; compare RSV to RSV+MG-132).
However, similar to the observed changes in NF-
B activation, the
luciferase activity in RSV-infected cells treated with 100 µM MG-132
was markedly greater than that in control cells.
|
The next set of experiments focused on determining whether the small
but statistically significant decrease in IL-8 gene transcription correlated with IL-8 protein production and release. For these experiments, the medium from control cells and RSV-infected cells was
collected 4 h after the medium was changed. Cells treated with
MG-132 received the agent at a concentration of 100 µM for 4 h.
Cell supernatants, representative of the release of IL-8 over 4 h,
were subjected to a previously described (9) enzyme-linked immunosorbent assay (ELISA) for IL-8. Cell lysates were also obtained after 4 h and subjected ELISA. As illustrated in Fig. 8B, RSV infection is associated with a marked increase in the amount of IL-8
released from the cells (error bars represent standard deviation for
the supernatant, P < 0.001 by ANOVA, n = 12) and the amount of cell-associated IL-8 (lysates, P < 0.001 by ANOVA, n = 12). However, treatment of
RSV-infected cells with 100 µM MG-132 for 4 h did not result in
any statistically significant difference in IL-8 release into the
supernatant or the cell-associated IL-8 (lysates) compared to untreated
RSV-infected cells. Thus, although inhibition of proteasome-mediated
I
B
degradation resulted in a small reversal of RSV-induced
NF-
B activation and NF-
B-mediated IL-8 gene transcription, no
significant change in IL-8 release or IL-8 production was observed.
The purpose of the study reported here was to determine whether
augmentation of endogenous I
B
protein levels would reverse RSV-induced NF-
B activation and NF-
B-mediated inflammation. Our findings indicate that RSV-induced I
B
protein production partially limits virus-induced NF-
B activation in A549 cells. Data
presented here indicate that RSV infection is associated with increased
I
B
mRNA expression and protein production. Limiting either
I
B
mRNA expression or protein production results in
exaggerated NF-
B activation in response to RSV infection.
Additionally, data presented here indicate that inhibition of
endogenous I
B
degradation did not reverse RSV-induced NF-
B
activation. Combined, these results indicate that endogenous
I
B
plays a role in limiting RSV-induced NF-
B activation
but cannot be recruited to completely reverse RSV-induced
NF-
B activation.
Recently Thomas et al. reported that adenovirus-mediated expression of
a nondegradable form of I
B
resulted in inhibition of RSV-induced
NF-
B activation and NF-
B-mediated RANTES production in airway
epithelial cells (20). The studies reported by Thomas et al.
differ from those presented here in two major respects. First, the
cells were transfected with the adenovirus-containing I
B
construct simultaneously with RSV infection. This enabled the cells to
produce nondegradable I
B
during the entire course of RSV
infection. In contrast, we did not treat the infected cells until RSV
infection had progressed for 2 days. Thus, one reason for the
differences in results observed maybe accounted for by experimental
design. Our studies were focused on reversing NF-
B activation after
it was initiated, whereas the studies of Thomas et al. were designed to
inhibit NF-
B activation from the initial point of infection.
A second difference between the studies involves their use of a mutant,
exogenous I
B
as opposed to our attempts to augment endogenous
I
B
protein levels. The recombinant I
B
was rendered resistant to phosphorylation and subsequent degradation by mutating serines at positions 32 and 36. Thus, any recombinant protein made by
the cells theoretically would not be degraded. In contrast, our studies
focused on maintaining the endogenous I
B
protein at control
levels, as this approach was successful with TNF-
stimulation
(10). Inhibition of proteasome degradation does not
alter I
B
phosphorylation. It is possible that
nonphosphorylated I
B
maintains interactions with NF-
B to a
greater degree than phosphorylated I
B
. Determining whether
phosphorylation of I
B
alters its interactions with p65 was beyond
the scope of this study.
Recently, Jamaluddin et al. reported that the major component of
I
B
proteolysis occurs independent of the proteasome pathway in
RSV-infected cells (14). In this study, the authors found that treatment with 25 µM Mg-132 for 4.5 h did not reverse
I
B
degradation. The results of our study, in comparison, indicate that treatment with MG-132 in dose range of 1 to 100 µg/ml for 2 h (all nontoxic as assayed by neutral red uptake) resulted in a
significant reversal of I
B
degradation. The 2-h treatment course
was chosen based on preliminary studies comparing treatment courses
with MG-132 of 20 min to 4 h. These studies demonstrated that peak
inhibition of I
B
degradation occurred at 2 h (data not
shown). The differences in our reported findings may be explained by
the fact that MG-132 is a reversible inhibitor of the proteasome, and
the optimal time course was chosen for our study.
Bitko and Barik recently reported on the persistent activation of the
RelA component of NF-
B by RSV (4); they demonstrated that
MG-132 (100 µM) reversed I
B
degradation and NF-
B activation at certain time points. The effects of MG-132 were reported as modest.
The authors also presented data which suggest that I
B
may act as
a chaperone for NF-
B, protecting it from I
B
inhibition. The
results presented here are consistent with the finding of Bitko and
Barik. The unsuccessful attempts to inhibit RSV-induced NF-
B
activation by increasing I
B
protein levels may be due to binding
of I
B
to NF-
B. This would suggest that a pool of NF-
B
(which can no longer be regulated by I
B
) is present in the
RSV-infected cells. An analysis of the role of I
B
was beyond the
scope of our study.
In summary, the study presented here focused on testing the hypothesis
that manipulation of I
B
levels would alter RSV-induced NF-
B
activation and NF-
B-mediated IL-8 production; the results do not
support this hypothesis. While RSV-induced I
B
synthesis does
limit NF-
B activation, complete reversal does not occur. Furthermore, augmentation of I
B
levels by inhibition of its degration does not reverse RSV-induced NF-
B activation.
While our results are not in complete agreement with those of Thomas et
al. (20) and Jamaluddin et al. (14), a recurrent finding is that RSV induces persistent NF-
B activation. The results presented here, along with those of Jamaluddin et al. and Bitko and
Barik, may begin to explain why some children with RSV infection have
persistent respiratory symptoms (1, 6, 21). It has been well
documented that inflammation plays a key role in RSV-induced morbidity
and mortality (6, 21). Persistent NF-
B-mediated inflammatory gene production in airway epithelial cells likely contributes to the morbidity associated with RSV infection.
Furthermore, this persistent inflammatory response may help explain the
morbidity associated with RSV infection in children with chronic
inflammatory airway disorders such as cystic fibrosis (1).
It will be critical in future studies to define the mechanisms by which
persistent NF-
B activation occurs, in order to begin to reverse the
inflammatory effects associated with its activation.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by grants from the NIH (HL03451 to M.A.F.) and the Cystic Fibrosis Foundation (FIEDLEGO97).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Pulmonary Medicine, Children's Hospital Research Foundation, 3333 Burnet Ave., Cincinnati, OH 45229-3039. Phone: (513) 636-6771. Fax: (513) 636-4615. E-mail: FIEDM0{at}CHMCC.ORG.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Abman, S. H., J. W. Ogle, N. Butler-Simon, C. M. Rumack, and F. J. Accurse. 1988. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J. Pediatr. 113:826-830[Medline]. |
| 2. | Arnold, R., B. Humber, H. Werchau, H. Galiati, and W. Konig. 1994. Interleukin-8, interleukin-6, and soluble tumor necrosis factor type II release from a human pulmonary epithelial cells line (A549) exposed to respiratory syncytial virus. Immunology 82:126-133[Medline]. |
| 3. |
Baldwin, A. S.
1996.
The NF- B and I B proteins: new discoveries and insights.
Annu. Rev. Immunol.
14:649-681[Medline].
|
| 4. |
Bitko, V., and S. Barik.
1998.
Persistent activation of RelA by respiratory syncytial virus involves protein kinase C, underphosphorylated I B , and sequestration of protein phosphatase 2A by the viral phosphoprotein.
J. Virol.
72:5610-5618 |
| 5. |
Bitko, V.,
A. Velayquey,
L. Yang,
Y.-C. Yang, and S. Barik.
1997.
Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF- B and is inhibited by sodium salicylate and aspirin.
Virology
232:369-378[Medline].
|
| 6. | Breese Hall, C. W., J. Hall, C. L. Gala, F. B. McGill, and J. P. Leddy. 1984. Long term prospective study in children after respiratory syncytial virus infection. J. Pediatr. 105:358-364[Medline]. |
| 7. |
Centers for Disease Control and Prevention.
1994.
Update: respiratory syncytial virus activity United States, 1994-1995 season.
Morbid. Mortal. Weekly Rep.
43:920-922[Medline].
|
| 8. |
Fiedler, M. A.,
K. Wernke-Dollries, and J. M. Stark.
1996.
Inhibition of viral replication reverses respiratory syncytial virus-induced NF- B activation and interleukin-8 gene expression in A549 cells.
J. Virol.
70:9079-9082[Abstract].
|
| 9. |
Fiedler, M. A.,
K. Wernke-Dollries, and J. M. Stark.
1996.
Mechanism of RSV-induced IL-8 gene expression in A549 cells before viral replication.
Am. J. Physiol.
271:L963-L971 |
| 10. |
Fiedler, M. A.,
K. Wernke-Dollries, and J. M. Stark.
1998.
Inhibition of TNF -induced NF- B activation and IL-8 release in A549 cells using the proteasome inhibitor MG-132.
Am. J. Respir. Cell Mol. Biol.
19:259-268 |
| 11. | Fiedler, M. A., K. Wernke-Dollries, and J. M. Stark. 1995. Respiratory syncytial virus increases IL-8 gene expression and protein release in A549 cells. Am. J. Physiol. 269:L872. |
| 12. | Garafalo, R., M. Sabry, M. Jamaluddin, R. K. Yu, A. Casola, P. L. Orga, and A. R. Brasier. 1996. Transcriptional activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar epithelial cells: nuclear translocation of the RelA transcription factor as a mechanism producing airway mucosal inflammation. J. Virol. 70:8773-8781[Abstract]. |
| 13. |
Ito, C. Y.,
A. G. Kazantsev, and A. S. Baldwin.
1994.
Three NF- B sites in the I B promoter are required for induction for gene expression by TNF .
Nucleic Acids Res.
22:3787-3792 |
| 14. |
Jamaluddin, M.,
A. Casola,
R. P. Garofalo,
Y. Han,
T. Elliot,
P. L. Ogra, and A. R. Basier.
1998.
A major component of I B proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells.
J. Virol.
72:4849-4857 |
| 15. | Mukaida, N., S. Okamoto, Y. Ishikawa, and K. Matsushima. 1994. Molecular mechanism of interleukin-8 expression. J. Leukoc. Biol. 56:554-558[Abstract]. |
| 16. | Mukaida, N. S., M. Shiroo, and K. Matsushima. 1989. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J. Immunol. 143:366-371[Abstract]. |
| 17. |
Murphy, E.,
K. Shibuya,
N. Hosken,
P. Openshaw,
B. Maino,
K. Davis,
K. Murphy, and A. O'Garra.
1996.
Reversibility of helper 1 and 2 populations is lost after long-term stimulation.
J. Exp. Med.
183:901-913 |
| 18. | Noah, T. L., F. W. Henderson, I. A. Wortman, R. B. Devlin, J. Handy, H. S. Koren, and S. Becker. 1995. Nasal cytokine production in viral acute upper respiratory infection of childhood. J. Infect. Dis. 171:584-592[Medline]. |
| 19. |
Openshaw, P.,
E. E. Murphy,
N. A. Hosken,
B. Maino,
K. Davis,
K. Murphy, and A. O'Garra.
1995.
Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations.
J. Exp. Med.
182:1357-1367 |
| 20. |
Thomas, L. H.,
J. S. Friedland,
M. Sharland, and S. Becker.
1998.
Respiratory syncytial virus induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor- B nuclear binding and is inhibited by adenovirus-mediated expression of inhibitor B .
J. Immunol.
161:1007-1016 |
| 21. |
Webb, M. S. C.,
R. L. Henry,
A. D. Milner,
G. M. Stokes, and A. S. Swarbuck.
1985.
Continuing respiratory problems three and a half years after acute viral bronchiolitis.
Arch. Dis. Child.
60:1064-1067 |
| 22. | Wong, H. R., M. Ryan, and J. R. Wispe. 1997. Stress response decreases NF-kappa B nuclear translocation and increases I-kappa B alpha expression in A549 cells. J. Clin. Investig. 99:2423-2428[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»